Multisystemic therapy versus management as usual in the treatment of adolescent antisocial behaviour (START): 5-year follow-up of a pragmatic, randomised, controlled, superiority trial.


Journal

The lancet. Psychiatry
ISSN: 2215-0374
Titre abrégé: Lancet Psychiatry
Pays: England
ID NLM: 101638123

Informations de publication

Date de publication:
05 2020
Historique:
received: 20 12 2019
revised: 17 02 2020
accepted: 13 03 2020
entrez: 1 5 2020
pubmed: 1 5 2020
medline: 2 7 2020
Statut: ppublish

Résumé

Multisystemic therapy is a manualised treatment programme for young people aged 11-17 years who exhibit antisocial behaviour. To our knowledge, the Systemic Therapy for At Risk Teens (START) trial is the first large-scale randomised controlled trial of multisystemic therapy in the UK. Previous findings reported to 18 months after baseline (START-I study) did not indicate superiority of multisystemic therapy compared with management as usual. Here, we report outcomes of the trial to 60 months (START-II study). In this pragmatic, randomised, controlled, superiority trial, young people (aged 11-17 years) with moderate-to-severe antisocial behaviour were recruited from social services, youth offending teams, schools, child and adolescent mental health services, and voluntary services across England, UK. Participants were eligible if they had at least three severity criteria indicating past difficulties across several settings and one of five general inclusion criteria for antisocial behaviour. Eligible families were randomly assigned (1:1), using stochastic minimisation and stratifying for treatment centre, sex, age at enrolment, and age at onset of antisocial behaviour, to management as usual or 3-5 months of multisystemic therapy followed by management as usual. Research assistants and investigators were masked to treatment allocation; the participants could not be masked. For this extension study, the primary outcome was the proportion of participants with offences with convictions in each group at 60 months after randomisation. This study is registered with ISRCTN, ISRCTN77132214, and is closed to accrual. Between Feb 4, 2010, and Sept 1, 2012, 1076 young people and families were assessed for eligibility and 684 were randomly assigned to management as usual (n=342) or multisystemic therapy (n=342). By 60 months' of follow-up, 188 (55%) of 342 people in the multisystemic therapy group had at least one offence with a criminal conviction, compared with 180 (53%) of 341 in the management-as-usual group (odds ratio 1·13, 95% CI 0·82-1·56; p=0·44). The results of the 5-year follow-up show no evidence of longer-term superiority for multisystemic therapy compared with management as usual. National Institute for Health Research Health Services and Delivery Research programme.

Sections du résumé

BACKGROUND
Multisystemic therapy is a manualised treatment programme for young people aged 11-17 years who exhibit antisocial behaviour. To our knowledge, the Systemic Therapy for At Risk Teens (START) trial is the first large-scale randomised controlled trial of multisystemic therapy in the UK. Previous findings reported to 18 months after baseline (START-I study) did not indicate superiority of multisystemic therapy compared with management as usual. Here, we report outcomes of the trial to 60 months (START-II study).
METHODS
In this pragmatic, randomised, controlled, superiority trial, young people (aged 11-17 years) with moderate-to-severe antisocial behaviour were recruited from social services, youth offending teams, schools, child and adolescent mental health services, and voluntary services across England, UK. Participants were eligible if they had at least three severity criteria indicating past difficulties across several settings and one of five general inclusion criteria for antisocial behaviour. Eligible families were randomly assigned (1:1), using stochastic minimisation and stratifying for treatment centre, sex, age at enrolment, and age at onset of antisocial behaviour, to management as usual or 3-5 months of multisystemic therapy followed by management as usual. Research assistants and investigators were masked to treatment allocation; the participants could not be masked. For this extension study, the primary outcome was the proportion of participants with offences with convictions in each group at 60 months after randomisation. This study is registered with ISRCTN, ISRCTN77132214, and is closed to accrual.
FINDINGS
Between Feb 4, 2010, and Sept 1, 2012, 1076 young people and families were assessed for eligibility and 684 were randomly assigned to management as usual (n=342) or multisystemic therapy (n=342). By 60 months' of follow-up, 188 (55%) of 342 people in the multisystemic therapy group had at least one offence with a criminal conviction, compared with 180 (53%) of 341 in the management-as-usual group (odds ratio 1·13, 95% CI 0·82-1·56; p=0·44).
INTERPRETATION
The results of the 5-year follow-up show no evidence of longer-term superiority for multisystemic therapy compared with management as usual.
FUNDING
National Institute for Health Research Health Services and Delivery Research programme.

Identifiants

pubmed: 32353277
pii: S2215-0366(20)30131-0
doi: 10.1016/S2215-0366(20)30131-0
pii:
doi:

Types de publication

Equivalence Trial Journal Article Pragmatic Clinical Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

420-430

Subventions

Organisme : Medical Research Council
ID : MC_UU_00002/6
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Auteurs

Peter Fonagy (P)

Research Department of Clinical, Educational and Health Psychology, University College London, London, UK. Electronic address: p.fonagy@ucl.ac.uk.

Stephen Butler (S)

Research Department of Clinical, Educational and Health Psychology, University College London, London, UK.

David Cottrell (D)

Leeds Institute of Health Sciences, University of Leeds, Leeds, UK.

Stephen Scott (S)

Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.

Stephen Pilling (S)

Research Department of Clinical, Educational and Health Psychology, University College London, London, UK.

Ivan Eisler (I)

Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.

Peter Fuggle (P)

Anna Freud National Centre for Children and Families, London, UK.

Abdullah Kraam (A)

Leeds Institute of Health Sciences, University of Leeds, Leeds, UK; Rotherham Doncaster and South Humber NHS Foundation Trust, Doncaster, UK.

Sarah Byford (S)

Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.

James Wason (J)

Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK; MRC Biostatistics Unit, University of Cambridge, Cambridge, UK.

Jonathan A Smith (JA)

Department of Psychological Sciences, Birkbeck College, University of London, London, UK.

Alisa Anokhina (A)

Research Department of Clinical, Educational and Health Psychology, University College London, London, UK.

Rachel Ellison (R)

Research Department of Clinical, Educational and Health Psychology, University College London, London, UK.

Elizabeth Simes (E)

Research Department of Clinical, Educational and Health Psychology, University College London, London, UK.

Poushali Ganguli (P)

Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.

Elizabeth Allison (E)

Research Department of Clinical, Educational and Health Psychology, University College London, London, UK.

Ian M Goodyer (IM)

Department of Psychiatry, University of Cambridge, Cambridge, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH